MAYZENT

This brand name is authorized in Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, United Kingdom, United States

Active ingredients

The drug MAYZENT contains one active pharmaceutical ingredient (API):

1 Siponimod UNII RR6P8L282I - SIPONIMOD

Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator. By acting as a functional antagonist on S1P1 receptors on lymphocytes, siponimod prevents egress from lymph nodes. This reduces the recirculation of T cells into the central nervous system (CNS) to limit central inflammation. Siponimod is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease. Read about Siponimod

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MAYZENT Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC
MAYZENT Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AE03		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AE Sphingosine-1-phosphate (S1P) receptor modulators
Discover more medicines within L04AE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 12158X, 12160B, 12172P
Country: CA	Health Products and Food Branch	Identifier(s): 02496429, 02496437
Country: EE	Ravimiamet	Identifier(s): 1809873, 1809884, 1809895, 1836334, 1836345, 1836356, 1875810, 1875821
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1191414001, 1191414003
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 098363, 414921, 532526
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 380800, 380801, 380804
Country: HK	Department of Health Drug Office	Identifier(s): 66875, 66876
Country: IE	Health Products Regulatory Authority	Identifier(s): 89118, 89119, 89120
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8521, 8721, 8722
Country: IT	Agenzia del Farmaco	Identifier(s): 048440010, 048440022, 048440034, 048440046, 048440059, 048440061, 048440073, 048440085
Country: JP	医薬品医療機器総合機構	Identifier(s): 3999051F1024, 3999051F2020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1089279, 1089280, 1089281, 1089618, 1090109, 1090110
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 202010, 202029
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 21327, 21328
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100432765, 100432771
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66696001, W66696002, W66696003, W66697001, W66697002, W66697003, W68730001, W68730002
Country: US	FDA, National Drug Code	Identifier(s): 0078-0979, 0078-0986